Chemokine inhibitors in the bullous pemphigoid pipeline may be the safest treatment for refractory patients

1 June 2020 (Last Updated June 1st, 2020 15:03)

Bullous pemphigoid is an autoimmune skin condition characterised by boils, rashes, and blisters, as well as prolonged inflammation and pruritus. The condition is painful, typically occurring in patients with ailments such as hypertension, diabetes, heart disease, and other autoimmune diseases such as lupus and rheumatoid arthritis.

Its pathology involves the formation of autoantibodies that target dystonin, a protein that is part of the plakin family associated with the cytoskeleton and multiprotein complexes at cell junctions. Read more here.